Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 1907 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others

REVIEW ARTICLE

Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement

Kalra Sanjay, Aamir A H, Raza Abbas, Das A K, Azad Khan A K, Shrestha Dina, Qureshi Md Faisal, Md Fariduddin, Pathan Md Faruque, Jawad Fatema, Bhattarai Jyoti, Tandon Nikhil, Somasundaram Noel, Katulanda Prasad, Sahay Rakesh, Dhungel Sanjib, Bajaj Sarita, Chowdhury Subhankar, Ghosh Sujoy, Madhu S V, Ahmed Tofail, Bulughapitiya Uditha

Year : 2015| Volume: 19| Issue : 5 | Page no: 577-596

   This article has been cited by
 
1 The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India
Sanjay Kalra,A. G. Unnikrishnan,Ganapathi Bantwal,Sambit Das,Nareen Krishna Polavarapu,Kumar Gaurav
Diabetes Therapy. 2021;
[Pubmed]  [Google Scholar] [DOI]
2 Role of Gliclazide in Safely Navigating Type 2 Diabetes Mellitus Patients Towards Euglycemia: Expert opinion from India
Subhash Wangnoo,M. Shunmugavelu,Sagili Vijaya Bhaskar Reddy,Vijay Negalur,Shreerang Godbole,Vinay K Dhandhania,Nareen Krishna,Kumar Gaurav
Endocrine and Metabolic Science. 2021; : 100102
[Pubmed]  [Google Scholar] [DOI]
3 Single Nucleotide Polymorphisms Associated with Metformin and Sulphonylureas’ Glycaemic Response among South African Adults with Type 2 Diabetes Mellitus
Charity Masilela,Brendon Pearce,Joven Jebio Ongole,Oladele Vincent Adeniyi,Mongi Benjeddou
Journal of Personalized Medicine. 2021; 11(2): 104
[Pubmed]  [Google Scholar] [DOI]
4 Gliclazide alters macrophages polarization state in diabetic atherosclerosis in vitro via blocking AGE-RAGE/TLR4-reactive oxygen species-activated NF-kß nexus
Humera Jahan,M. Iqbal Choudhary
European Journal of Pharmacology. 2021; : 173874
[Pubmed]  [Google Scholar] [DOI]
5 Sulfonylurea, an Update
Tae Nyun Kim
The Journal of Korean Diabetes. 2021; 22(2): 105
[Pubmed]  [Google Scholar] [DOI]
6 Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
Joăo V. S. Guerra,Marieli M. G. Dias,Anna J. V. C. Brilhante,Maiara F. Terra,Marta García-Arévalo,Ana Carolina M. Figueira
Nutrients. 2021; 13(8): 2830
[Pubmed]  [Google Scholar] [DOI]
7 Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma
Hyunkoo Kang,Sungmin Lee,Kyeongmin Kim,Jaewan Jeon,Seok-Gu Kang,HyeSook Youn,Hae Yu Kim,BuHyun Youn
Journal of Experimental & Clinical Cancer Research. 2021; 40(1)
[Pubmed]  [Google Scholar] [DOI]
8 Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives
Kamlesh Khunti,Mohamed Hassanein,Moon-Kyu Lee,Viswanathan Mohan,Aslam Amod
Diabetes Therapy. 2020;
[Pubmed]  [Google Scholar] [DOI]
9 Role of Carnitine on Hematological Parameters and Attenuation of Cardiac (Pro)renin Receptor and Caspase-3 Expression in Hypoglycemia-induced Cardiac Hypertrophy
Wael A. Alanazi
International Journal of Pharmacology. 2020; 16(3): 191
[Pubmed]  [Google Scholar] [DOI]
10 Evaluation of type 2 diabetes treatment with gliclazide modified release in Azerbaijan (the EdiAzer study): Results from a 16-week observational clinical study
ValehA Mirzazada,RamilaA Huseynova,SevilA Mustafayeva,FidanN Gasimova,Ulviyya Ahmadova,Narmin Ismayilova,Vafa Kerimova,Hagigat Mehdiyeva,Rana Suleymanova,Zahrakhanim Maharramova,Gulnara Iskandarli,Ofeliya Gurbanova,Sariyya Aghayeva,Sabina Malikova,Konul Ismayilova,Khanim Salimkhanova
Journal of Diabetology. 2020; 11(3): 175
[Pubmed]  [Google Scholar] [DOI]
11 Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence
Rakesh Kumar Sahay,Vinod Mittal,G Raja Gopal,Sunil Kota,Ghanshyam Goyal,Mahesh Abhyankar,Santosh Revenkar
Cureus. 2020;
[Pubmed]  [Google Scholar] [DOI]
12 RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Rajeev Chawla,SV Madhu,BM Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra
Indian Journal of Endocrinology and Metabolism. 2020; 24(1): 1
[Pubmed]  [Google Scholar] [DOI]
13 A real-world study in patients with type 2 diabetes mellitus treated with gliclazide modified-release during fasting: DIA-RAMADAN
Mohamed Hassanein,Saud Al Sifri,Shehla Shaikh,Syed Abbas Raza,Javed Akram,Agung Pranoto,Achmad Rudijanto,Inass Shaltout,Md Fariduddin,Wan Mohd Izani Wan Mohamed,Fatheya Al Awadi,Thamer Alessa
Diabetes Research and Clinical Practice. 2020; 163: 108154
[Pubmed]  [Google Scholar] [DOI]
14 New combination therapy of gliclazide and quercetin for protection against STZ-induced diabetic rats
Noha F. Abdelkader,Hebatollah E. Eitah,Yousreya A. Maklad,Amina A. Gamaleldin,Manal A. Badawi,Sanaa A. Kenawy
Life Sciences. 2020; : 117458
[Pubmed]  [Google Scholar] [DOI]
15 Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
Nina A. Petunina,Irina A. Kuzina,Ludmila V. Nedosugova
Diabetes mellitus. 2020; 23(4): 357
[Pubmed]  [Google Scholar] [DOI]
16 The Place of Sulfonylureas in the Evolving Landscape of Combination Therapy
Miao Yu
Diabetes Therapy. 2020;
[Pubmed]  [Google Scholar] [DOI]
17 RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Rajeev Chawla,S. V. Madhu,B. M. Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra
International Journal of Diabetes in Developing Countries. 2020; 40(S1): 1
[Pubmed]  [Google Scholar] [DOI]
18 Scientific considerations for global drug development
Jennifer L. Wilson,Kit Wun Kathy Cheung,Lawrence Lin,Elizabeth A. E. Green,Analia I. Porrás,Ling Zou,David Mukanga,Paul A. Akpa,Delese Mimi Darko,Rae Yuan,Sheng Ding,Wiltshire C. N. Johnson,Howard A. Lee,Emer Cooke,Carl C. Peck,Steven E. Kern,Dan Hartman,Yoshikazu Hayashi,Peter W. Marks,Russ B. Altman,Murray M. Lumpkin,Kathleen M. Giacomini,Terrence F. Blaschke
Science Translational Medicine. 2020; 12(554): eaax2550
[Pubmed]  [Google Scholar] [DOI]
19 The Place of Sulfonylureas in Guidelines: Why Are There Differences?
Aslam Amod
Diabetes Therapy. 2020;
[Pubmed]  [Google Scholar] [DOI]
20 Introduction: Real-World Evidence in Type 2 Diabetes
Mohamed Hassanein,Aslam Amod,Kamlesh Khunti,Moon-Kyu Lee,Viswanathan Mohan
Diabetes Therapy. 2020;
[Pubmed]  [Google Scholar] [DOI]
21 Missing the wood for the trees: cardiocentricity in current diabetes guidelines
Sanjay Kalra,Banshi Saboo,Nagendra Kumar Singh,Sarita Bajaj
International Journal of Diabetes in Developing Countries. 2020;
[Pubmed]  [Google Scholar] [DOI]
22 A lion in the room: Has the CAROLINA trial definitely resolved the issue of the cardiovascular safety of sulfonylureas?
Theocharis Koufakis,George Dimitriadis,Kalliopi Kotsa
Journal of Diabetes. 2020;
[Pubmed]  [Google Scholar] [DOI]
23 Unravelling the Utility of Modern Sulfonylureas From CVOTs and Landmark Trials: Expert Opinion from an International Panel
S. Kalra,S. Ghosh,A.K. Das,T. Nair,S. Bajaj,G. Priya,R.N. Mehrotra,S. Das,P. Shah,V. Deshmukh,M. Chawla,D. Sanyal,S. Chandrasekaran,D. Khandelwal,A. Joshi,F. Eliana,H. Permana,M.D. Fariduddin,P.K. Shrestha,D. Shrestha,S. Kahandawa,M. Sumanathilaka,A. Shaheed,A.A. Rahim,A. Orabi,A. Al-ani,W. Hussein,D. Kumar,K. Shaikh
Indian Heart Journal. 2020;
[Pubmed]  [Google Scholar] [DOI]
24 Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes
Natalia ?. Trubitsyna,Marina V. Shestakova
Diabetes mellitus. 2019; 22(2): 159
[Pubmed]  [Google Scholar] [DOI]
25 In Silico Analysis of New Potent Anti-hyperglycemic Molecule for Diabetes Type 2 Management
Kritika Singh,Praveen Kumar Tripathi,Vinay Kumar Singh,Ashok Kumar Patel,O. N. Srivastava,S. K. Singh,Arvind M. Kayastha
International Journal of Peptide Research and Therapeutics. 2019;
[Pubmed]  [Google Scholar] [DOI]
26 Management of Type 2 Diabetes in Developing Countries: Balancing Optimal Glycaemic Control and Outcomes with Affordability and Accessibility to Treatment
Viswanathan Mohan,Kamlesh Khunti,Siew P. Chan,Fadlo F. Filho,Nam Q. Tran,Kaushik Ramaiya,Shashank Joshi,Ambrish Mithal,Maďmouna N. Mbaye,Nemencio A. Nicodemus,Tint S. Latt,Linong Ji,Ibrahim N. Elebrashy,Jean C. Mbanya
Diabetes Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]
27 Antidiabetic agents in patients with hepatic impairment
Athanasia Papazafiropoulou,Andreas Melidonis
World Journal of Meta-Analysis. 2019; 7(8): 380
[Pubmed]  [Google Scholar] [DOI]
28 National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus
Jisu Kim,Susin Park,Hyunsoo Kim,Nam Kyung Je
European Journal of Clinical Pharmacology. 2019;
[Pubmed]  [Google Scholar] [DOI]
29 Long-Term Clinical Benefits of Canagliflozin 100 mg versus Sulfonylurea in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin in India
Vishal Gupta,Michael Willis,Pierre Johansen,Andreas Nilsson,Manan Shah,Amey Mane,Cheryl Neslusan
Value in Health Regional Issues. 2019; 18: 65
[Pubmed]  [Google Scholar] [DOI]
30 Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group
Sanjay Kalra,A. K. Das,M. P. Baruah,A. G. Unnikrishnan,Arundhati Dasgupta,Parag Shah,Rakesh Sahay,Rishi Shukla,Sambit Das,Mangesh Tiwaskar,G. Vijayakumar,Manoj Chawla,Fatimah Eliana,Ketut Suastika,Abbas Orabi,Aly Ahmed Abdul Rahim,Andrew Uloko,Silver Bahendeka,Abdurezak Ahmed Abdela,Fariduddin Mohammed,Faruque Pathan,Muhammed Hafizur Rahman,Faria Afsana,Shajada Selim,Muaz Moosa,Moosa Murad,Pradeep Krishna Shreshtha,Dina Shreshtha,Mimi Giri,Wiam Hussain,Ahmed Al-Ani,Kaushik Ramaiya,Surender Singh,Syed Abbas Raza,Than Than Aye,Chaminda Garusinghe,Dimuthu Muthukuda,Muditha Weerakkody,Shyaminda Kahandawa,Charlotte Bavuma,Sundeep Ruder,Koy Vanny,Manish Khanolkar,Leszek Czupryniak
Diabetes Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]
31 BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion
Sarita Bajaj,A. K. Das,Sanjay Kalra,Rakesh Sahay,Banshi Saboo,Sambit Das,M. Shunmugavelu,Jubbin Jacob,Gagan Priya,Deepak Khandelwal,Deep Dutta,Manoj Chawla,Vineet Surana,Mangesh Tiwaskar,Ameya Joshi,Pradip Krishna Shrestha,Jyoti Bhattarai,Bishwajit Bhowmik,Tint Swe Latt,Than Than Aye,G. Vijayakumar,Manash Baruah,Fatema Jawad,A. G. Unnikrishnan,Subhankar Chowdhury,Md. Faruqe Pathan,Noel Somasundaram,Manilka Sumanathilaka,Abbas Raza,Silver K. Bahendeka,Ankia Coetzee,Sundeep Ruder,Kaushik Ramaiya,Roberta Lamptey,Charlotte Bavuma,Khalid Shaikh,Andrew Uloko,Sandeep Chaudhary,Abdurezak Ahmed Abdela,Zhanay Akanov,Joel Rodrěguez-Saldańa,Raquel Faradji,Armindo Tiago,Ahmed Reja,Leszek Czupryniak
Diabetes Therapy. 2019;
[Pubmed]  [Google Scholar] [DOI]
32 Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice
Dana M. Niedowicz,Sabire Özcan,Peter T. Nelson
Journal of Diabetes Research. 2018; 2018: 1
[Pubmed]  [Google Scholar] [DOI]
33 Bonus Effects of Antidiabetic Drugs: Possible Beneficial Effects on Endothelial Dysfunction, Vascular Inflammation and Atherosclerosis
Camila A. Pereira,Fernando S. Carneiro,Takayuki Matsumoto,Rita C. Tostes
Basic & Clinical Pharmacology & Toxicology. 2018;
[Pubmed]  [Google Scholar] [DOI]
34 The place of gliclazide MR in the evolving type 2 diabetes landscape: A comparison with other sulfonylureas and newer oral antihyperglycemic agents
Stephen Colagiuri,David Matthews,Lawrence A. Leiter,Siew Pheng Chan,Giorgio Sesti,Michel Marre
Diabetes Research and Clinical Practice. 2018; 143: 1
[Pubmed]  [Google Scholar] [DOI]
35 Modern Sulfonylureas Strike Back – Exploring the Freedom of Flexibility
Sanjay Kalra,Deepak Khandelwal
European Endocrinology. 2018; 14(2): 20
[Pubmed]  [Google Scholar] [DOI]
36 Sulfonylureas at the Glomerular Battlefield
Sanjay Kalra,Deepak Khandelwal,Sarita Bajaj,Ashok Kumar Das
European Endocrinology. 2018; 14(2): 15
[Pubmed]  [Google Scholar] [DOI]
37 Sulfonyl(thio)urea derivative induction of insulin secretion is mediated by potassium, calcium, and sodium channel signal transduction
Paola Miranda Sulis,Betina Fernanda Dambrós,Alessandra Mascarello,Adair Roberto Soares dos Santos,Rosendo Augusto Yunes,Ricardo José Nunes,Marisa Jádna Silva Frederico,Fátima Regina Mena Barreto Silva
Journal of Cellular Physiology. 2018;
[Pubmed]  [Google Scholar] [DOI]
38 Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial
Lawrence A. Leiter,Marina V. Shestakova,Ilhan Satman
Diabetology & Metabolic Syndrome. 2018; 10(1)
[Pubmed]  [Google Scholar] [DOI]
39 Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association
Annabelle Santos Volgman,Latha S. Palaniappan,Neelum T. Aggarwal,Milan Gupta,Abha Khandelwal,Aruna V. Krishnan,Judith H. Lichtman,Laxmi S. Mehta,Hena N. Patel,Kevin S. Shah,Svati H. Shah,Karol E. Watson
Circulation. 2018; 138(1)
[Pubmed]  [Google Scholar] [DOI]
40 Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
Sanjay Kalra,Silver Bahendeka,Rakesh Sahay,Sujoy Ghosh,Fariduddin Md,Abbas Orabi,Kaushik Ramaiya,Sameer Al Shammari,Dina Shrestha,Khalid Shaikh,Sachitha Abhayaratna,PradeepK Shrestha,Aravinthan Mahalingam,Mazen Askheta,AlyAhmed A. Rahim,Fatimah Eliana,HariK Shrestha,Sandeep Chaudhary,Nancy Ngugi,JeanClaude Mbanya,ThanThan Aye,TintSwe Latt,ZhanayA Akanov,AbbasRaza Syed,Nikhil Tandon,AG Unnikrishnan,SV Madhu,Ali Jawa,Subhankar Chowdhury,Sarita Bajaj,AshokKumar Das
Indian Journal of Endocrinology and Metabolism. 2018; 22(1): 132
[Pubmed]  [Google Scholar] [DOI]
41 Clinical practice points for diabetes management during RAMADAN fast
Shaukat Sadikot,K. Jothydev,A.H. Zargar,Jamal Ahmad,S.R. Arvind,Banshi Saboo
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;
[Pubmed]  [Google Scholar] [DOI]
42 New Medications for the Treatment of Diabetes
Satish K. Garg,Dominique Giordano,Tyler Gallo,Viral N. Shah
Diabetes Technology & Therapeutics. 2017; 19(S1): S-128
[Pubmed]  [Google Scholar] [DOI]
43 Mortality and Cardiovascular Risk of Sulfonylureas in South Asian, Chinese and Other Canadians with Diabetes
Calvin Ke,Steve Morgan,Kate Smolina,Danijela Gasevic,Hong Qian,Nadia Khan
Canadian Journal of Diabetes. 2016;
[Pubmed]  [Google Scholar] [DOI]
44 Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial
S. T. Azar,A. Echtay,W. M. Wan Bebakar,S. Al Araj,A. Berrah,M. Omar,A. Mutha,K. Tornře,M. S. Kaltoft,N. Shehadeh
Diabetes, Obesity and Metabolism. 2016;
[Pubmed]  [Google Scholar] [DOI]
45 Challenges in diabetes mellitus type 2 management in Nepal: a literature review
Bishal Gyawali,Alessandra Ferrario,Edwin van Teijlingen,Per Kallestrup
Global Health Action. 2016; 9(1): 31704
[Pubmed]  [Google Scholar] [DOI]
46 Genetic variations in TCF7L2 influence therapeutic response to sulfonylureas in Indian diabetics
Dipali Dhawan,Harish Padh
Diabetes Research and Clinical Practice. 2016; 121: 35
[Pubmed]  [Google Scholar] [DOI]

 

Read this article